Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease

I148M variant of PNPLA3 increases the susceptibility to non-alcoholic fatty liver disease caused by obesity and metabolic disorders

(2016) M.-F. Xia et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Nonalcoholic Fatty Liver Disease Is Prevalent in Women With Prior Gestational Diabetes Mellitus and Independently Associated With Insulin Resistance and Waist Circumference

(2016) Signe Foghsgaard et al.   DIABETES CARE

Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD

(2016) Alexandra Montagner et al.   GUT

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

(2016) Zobair M. Younossi et al.   HEPATOLOGY

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

(2016)   JOURNAL OF HEPATOLOGY

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

(2016) Matthew James Armstrong et al.   LANCET

Fatty liver indexvswaist circumference for predicting non-alcoholic fatty liver disease

(2016) Nima Motamed et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Nutrition and Physical Activity in Nonalcoholic Fatty Liver Disease

(2016) Claudia P. Oliveira et al.   Journal of Diabetes Research

Non-alcoholic steatohepatitis-related liver cirrhosis is increasing in China: A ten-year retrospective study

(2015) J Xiong et al.   Clinics

Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies

(2015) Wenjuan Tang et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels

(2015) Paola Portillo-Sanchez et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Assessment of liver fat content using quantitative ultrasonography to evaluate risks for metabolic diseases

(2015) Ming-Feng Xia et al.   Obesity

Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes

(2014) Yan Bi et al.   ACTA DIABETOLOGICA

Review article: the management of paediatric nonalcoholic fatty liver disease

(2014) E. B. Mitchel et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Metformin alleviates hepatosteatosis by restoring SIRT1-mediated autophagy induction via an AMP-activated protein kinase-independent pathway

(2014) Young Mi Song et al.   Autophagy

Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes

(2014) Ning Shao et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis

(2013) J. E. Schopman et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Effects of Liraglutide, a Human Glucagon-like Peptide-1 Analogue, on Body Weight, Body Fat Area and Body Fat-related Markers in Patients with Type 2 Diabetes Mellitus

(2013) Daisuke Suzuki et al.   INTERNAL MEDICINE

Prevalence and Control of Diabetes in Chinese Adults

(2013) Yu Xu   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Nonalcoholic Fatty Liver Disease: A Novel Cardiometabolic Risk Factor for Type 2 Diabetes and Its Complications

(2013) Giovanni Targher et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Quantitative chemical shift-encoded MRI is an accurate method to quantify hepatic steatosis

(2013) Jens-Peter Kühn et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

The global NAFLD epidemic

(2013) Rohit Loomba et al.   Nature Reviews Gastroenterology & Hepatology

Effects of a novel therapeutic diet on liver enzymes and coagulating factors in patients with non-alcoholic fatty liver disease: A parallel randomized trial

(2013) Ali Hashemi Kani et al.   NUTRITION

Glycemic Variability Is an Independent Predictive Factor for Development of Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease

(2013) Motoi Hashiba et al.   PLoS One

Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: the Edinburgh Type 2 Diabetes Study

(2011) R. M. Williamson et al.   DIABETES CARE

Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: A 12-month randomized, prospective, open- label trial

(2011) Dawn M. Torres et al.   HEPATOLOGY

Standardized Ultrasound Hepatic/Renal Ratio and Hepatic Attenuation Rate to Quantify Liver Fat Content: An Improvement Method

(2011) Ming-Feng Xia et al.   Obesity

Exenatide in the Treatment of Diabetic Patients With Non-Alcoholic Steatohepatitis: A Case Series

(2010) Patrick R Kenny et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes

(2009) Alok K. Gupta et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Magnetic resonance imaging and spectroscopy accurately estimate the severity of steatosis provided the stage of fibrosis is considered

(2009) Stuart McPherson et al.   JOURNAL OF HEPATOLOGY